Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRON-DEP trial of intravenous versus oral iron after caesarean delivery
2023-503283-17-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose and ferrous sulfate in iron deficiency anemia (IDA) and postpartum depression (PPD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Prevalence of postpartum depression symptoms at 8 weeks postpartum. Planned start Apr 2024; status: authorised.
02
Drugs
ferric carboxymaltoseferrous sulfate
03
Conditions
iron deficiency anemia (IDA)postpartum depression (PPD)
Beyond the preview
Go deeper on 2023-503283-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503283-17-00.